RJA
AEGR

Raymond James & Associates’s Aegerion Pharmaceuticals AEGR Stock Holding History

Raymond James & Associates’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-21,069
Closed -$1.33M – 2029
2013
Q2 		$1.33M Buy
+21,069
New +$1.12M 0.01% 1025

Other funds holding AEGR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Raymond James & Associates's AEGR Position: Q3 2013 in Review

Raymond James & Associates sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2013, closing a stake of 21,069 shares — an estimated $1.33M sold.

Raymond James & Associates first reported a position in AEGR in Q2 2013 and held it in 1 quarter. The position peaked at $1.33M in Q2 2013. 154 funds tracked by Wall St. Rank hold AEGR as of Q3 2013.

  • Raymond James & Associates reported no remaining Aegerion Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Raymond James & Associates sold 21,069 Aegerion Pharmaceuticals shares in Q3 2013, an estimated $1.33M.
  • Raymond James & Associates first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Raymond James & Associates's Aegerion Pharmaceuticals position peaked at $1.33M in Q2 2013.
  • 154 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2013.

Based on Raymond James & Associates's 13F filing for Q3 2013, filed 13 Nov 2013.